{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:01:48Z","timestamp":1788123708817,"version":"build-2803163510"},"reference-count":35,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human cytomegalovirus (CMV) reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Despite routine screening for CMV reactivation and early antiviral treatment, the rates of CMV-related complications after HCT remain high. Genetic variants in both the donor and recipient have been associated with the risk of CMV reactivation and disease after HCT, but these associations have not been validated, and their clinical importance remains unclear. In this study, we assessed 117 candidate variants previously associated with CMV-related phenotypes for association with CMV reactivation and disease in a cohort of 2169 CMV-seropositive HCT recipients. We also carried out a genome-wide association study (GWAS) for CMV reactivation and disease in the same cohort. Both analyses used a prespecified discovery and replication approach to control the risk of false-positive results. Among the 117 candidate variants, our analysis implicates only the donor ABCB1 rs1045642 genotype as a risk factor for CMV reactivation. This synonymous variant in P-glycoprotein may influence the risk of CMV reactivation by altering the efflux of cyclosporine and tacrolimus from donor lymphocytes. In the GWAS analysis, the donor CDC42EP3 rs11686168 genotype approached the significance threshold for association with CMV reactivation, although we could not identify a mechanism to explain this association. The results of this study suggest that most genomic variants previously associated with CMV phenotypes do not significantly alter the risk for CMV reactivation or disease after HCT.<\/jats:p>","DOI":"10.1182\/blood.2021012153","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T15:54:41Z","timestamp":1626450881000},"page":"1628-1636","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8332-8578","authenticated-orcid":false,"given":"Amanda M.","family":"Casto","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA;"},{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4308-2152","authenticated-orcid":false,"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-570X","authenticated-orcid":false,"given":"David M.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA;"},{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-1215","authenticated-orcid":false,"given":"Paul J.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2022012421150805900_B1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1083-8791(00)70010-3","article-title":"CMV antigenemia following bone marrow transplantation: risk factors and outcomes","volume":"6","author":"Osarogiagbon","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022012421150805900_B2","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/bmt.2008.120","article-title":"CMV infections after hematopoietic stem cell transplantation","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"2022012421150805900_B3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022012421150805900_B4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis."},{"issue":"3","key":"2022012421150805900_B5","doi-asserted-by":"crossref","first-page":"e13548","DOI":"10.1111\/tid.13548","article-title":"Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance","volume":"23","author":"Lindsay","year":"2021","journal-title":"Transpl Infect Dis."},{"issue":"11","key":"2022012421150805900_B6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs."},{"issue":"4","key":"2022012421150805900_B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5500\/wjt.v5.i4.287","article-title":"Cytomegalovirus infection in the bone marrow transplant patient","volume":"5","author":"Bhat","year":"2015","journal-title":"World J Transplant."},{"issue":"2","key":"2022012421150805900_B8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3062.2011.00706.x","article-title":"A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group","volume":"14","author":"George","year":"2012","journal-title":"Transpl Infect Dis."},{"issue":"4","key":"2022012421150805900_B9","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O\u2019Brien","year":"2008","journal-title":"Blood."},{"issue":"2","key":"2022012421150805900_B10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"3","author":"Nguyen","year":"2002","journal-title":"Clin Lymphoma."},{"issue":"10","key":"2022012421150805900_B11","first-page":"1248","article-title":"Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir","volume":"89","author":"Laurenti","year":"2004","journal-title":"Haematologica."},{"issue":"20","key":"2022012421150805900_B12","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2022012421150805900_B13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/JCM.44.5.1847-1850.2006","article-title":"Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation","volume":"44","author":"Loeffler","year":"2006","journal-title":"J Clin Microbiol."},{"issue":"2","key":"2022012421150805900_B14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jmv.24050","article-title":"Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes","volume":"87","author":"Corrales","year":"2015","journal-title":"J Med Virol."},{"issue":"7","key":"2022012421150805900_B15","doi-asserted-by":"crossref","first-page":"e0200221","DOI":"10.1371\/journal.pone.0200221","article-title":"Impact of IFN lambda 3\/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients","volume":"13","author":"Annibali","year":"2018","journal-title":"PLoS One."},{"issue":"5","key":"2022012421150805900_B16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/jmv.23865","article-title":"Effect of the IL28B Rs12979860 C\/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients","volume":"86","author":"Bravo","year":"2014","journal-title":"J Med Virol."},{"issue":"1","key":"2022012421150805900_B17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajhg.2015.12.001","article-title":"Genetic diversity and association studies in US Hispanic\/Latino populations: applications in the Hispanic Community Health Study\/Study of Latinos","volume":"98","author":"Conomos","year":"2016","journal-title":"Am J Hum Genet."},{"issue":"6","key":"2022012421150805900_B18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbmt.2009.02.009","article-title":"Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation","volume":"15","author":"Nakamae","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2022012421150805900_B19","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"14","key":"2022012421150805900_B20","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/bloodadvances.2020001927","article-title":"Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation","volume":"4","author":"Martin","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2022012421150805900_B21","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022012421150805900_B22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis."},{"issue":"4","key":"2022012421150805900_B23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FTD.0b013e31828c1581","article-title":"Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus","volume":"35","author":"Vafadari","year":"2013","journal-title":"Ther Drug Monit."},{"issue":"11","key":"2022012421150805900_B24","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/00498254.2018.1563732","article-title":"Effects of MDR1 1236C\u2009&gt;\u2009T-2677G\u2009&gt;\u2009T-3435C\u2009&gt;\u2009T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus","volume":"49","author":"Wang","year":"2019","journal-title":"Xenobiotica."},{"issue":"5","key":"2022012421150805900_B25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics."},{"issue":"4","key":"2022012421150805900_B26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/FPC.0b013e3282f7046f","article-title":"Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients","volume":"18","author":"Crettol","year":"2008","journal-title":"Pharmacogenet Genomics."},{"issue":"2","key":"2022012421150805900_B27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/187231208784040951","article-title":"Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers","volume":"2","author":"Ansermot","year":"2008","journal-title":"Drug Metab Lett."},{"issue":"6","key":"2022012421150805900_B28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1681\/ASN.2008080819","article-title":"ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome","volume":"20","author":"Cattaneo","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"5811","key":"2022012421150805900_B29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science."},{"issue":"9","key":"2022012421150805900_B30","doi-asserted-by":"crossref","first-page":"e0222336","DOI":"10.1371\/journal.pone.0222336","article-title":"Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype","volume":"14","author":"Funakoshi","year":"2019","journal-title":"PLoS One."},{"issue":"6","key":"2022012421150805900_B31","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1042\/BST20160219","article-title":"The Borg family of Cdc42 effector proteins Cdc42EP1-5","volume":"44","author":"Farrugia","year":"2016","journal-title":"Biochem Soc Trans."},{"issue":"1","key":"2022012421150805900_B32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.celrep.2016.05.070","article-title":"Cytomegalovirus restructures lipid rafts via a US28\/CDC42-mediated pathway, enhancing cholesterol efflux from host cells","volume":"16","author":"Low","year":"2016","journal-title":"Cell Rep."},{"issue":"4","key":"2022012421150805900_B33","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.4049\/jimmunol.1100253","article-title":"Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling","volume":"187","author":"Fessler","year":"2011","journal-title":"J Immunol."},{"issue":"5","key":"2022012421150805900_B34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MOL.0000000000000106","article-title":"Interaction of pathogens with host cholesterol metabolism","volume":"25","author":"Sviridov","year":"2014","journal-title":"Curr Opin Lipidol."},{"issue":"3","key":"2022012421150805900_B35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/21541248.2016.1223533","article-title":"Cdc42 - A tryst\u00a0between host cholesterol metabolism and infection","volume":"9","author":"Sviridov","year":"2018","journal-title":"Small GTPases."}],"updated-by":[{"DOI":"10.1182\/blood.2022015702","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/17\/1628\/1864421\/bloodbld2021012153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/17\/1628\/1864421\/bloodbld2021012153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T21:15:39Z","timestamp":1643058939000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/17\/1628\/476416\/Genetic-variants-associated-with-cytomegalovirus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021012153","relation":{"correction":[{"id-type":"doi","id":"10.1182\/blood.2022015702","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}